Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Peter Impey

- PMLiVE

AZ and Clovis PARP inhibitors show their mettle at ESMO

Lynparza and Rubraca both on track to extend cancer patient reach

- PMLiVE

Dynavax is ‘deal-ready’ after solid ESMO data; analyst

Contrasting results for two novel immunotherapies

- PMLiVE

AZ and Medicines Catapult collaborate on innovative sound tech in drug discovery

Collaborates with Medicines Discovery Catapult on AMI-MS

Artificial intelligence in healthcare

What are the benefits for pharma?

- PMLiVE

Shire’s angioedema drug Takhzyro recommended in Europe

Analysts expect the drug to make around $1.8bn in peak sales

- PMLiVE

UK ‘unicorn’ Oxford Nanopore bags $65m backing from Amgen

Big biopharma investment good news for gene sequencing company

Osteoporosis

Cuttsy+Cuttsy launch their latest patient e-book

On the eve of ‘World Osteoporosis Day’ (worldosteoporosisday.org), Cuttsy+Cuttsy are proud to launch their latest e-book ‘Osteoporosis…in plain English’.

Cuttsy + Cuttsy

- PMLiVE

McCann Health London launch Urban Eye Test

Initiative aims to encourage the public to check their vision

Let’s throw it against the wall and see what sticks…

Why including drug costs in DTC advertising is an idea full of holes

Big Pharma, Little Pharma

Evolution provides options for those firms that can’t be huge

- PMLiVE

AI UK – one year on

Are patients still cautiously embracing new healthcare tools?

- PMLiVE

Novartis buys cancer specialist Endocyte for $2.1bn

Acquisition includes 'universal' CAR-T platform

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links